Analysts’ Top Healthcare Picks: Apellis Pharmaceuticals (APLS), Argenx Se (ARGX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Apellis Pharmaceuticals (APLS – Research Report) and Argenx Se (ARGX – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Apellis Pharmaceuticals (APLS)
In a report released today, Adam Walsh from Roth MKM initiated coverage with a Buy rating on Apellis Pharmaceuticals and a price target of $31.00. The company’s shares closed last Thursday at $18.39.
According to TipRanks.com, Walsh is a 4-star analyst with an average return of
Currently, the analyst consensus on Apellis Pharmaceuticals is a Moderate Buy with an average price target of $31.53, representing a 63.7% upside. In a report issued on March 2, William Blair also maintained a Buy rating on the stock.
See today’s best-performing stocks on TipRanks >>
Argenx Se (ARGX)
In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Argenx Se, with a price target of $1146.00. The company’s shares closed last Thursday at $708.85.
According to TipRanks.com, Werber is a 5-star analyst with an average return of
Argenx Se has an analyst consensus of Strong Buy, with a price target consensus of $1036.18, representing a 43.7% upside. In a report issued on February 26, William Blair also maintained a Buy rating on the stock.
